These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients. Lin P; Bueso-Ramos C; Wilson CS; Mansoor A; Medeiros LJ Am J Surg Pathol; 2003 Aug; 27(8):1104-13. PubMed ID: 12883242 [TBL] [Abstract][Full Text] [Related]
3. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000 [TBL] [Abstract][Full Text] [Related]
6. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506 [TBL] [Abstract][Full Text] [Related]
7. Macroglobulinemia and chronic B-cell type lymphocytic leukemia in japan--study of autopsy cases. Kikuchi M; Mitsui T; Takeshita M; Okamura H Jpn J Clin Oncol; 1983 Sep; 13(3):607-22. PubMed ID: 6417377 [TBL] [Abstract][Full Text] [Related]
8. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia. Pasricha SR; Juneja SK; Westerman DA; Came NA J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic spectrum of Waldenström's macroglobulinemia: a single center experience. Sajid R; Siddiqui SH; Shaikh U; Adil S Indian J Pathol Microbiol; 2010; 53(3):490-3. PubMed ID: 20699509 [TBL] [Abstract][Full Text] [Related]
10. Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia. Tripsas CK; Patterson CJ; Uljon SN; Lindeman NI; Turnbull B; Treon SP Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):250-2. PubMed ID: 23664027 [TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells. de Tute RM; Rawstron AC; Owen RG Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):211-3. PubMed ID: 23523273 [TBL] [Abstract][Full Text] [Related]
12. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia. Jalali S; Ansell SM Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460 [TBL] [Abstract][Full Text] [Related]
13. Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Owen RG; Barrans SL; Richards SJ; O'Connor SJ; Child JA; Parapia LA; Morgan GJ; Jack AS Am J Clin Pathol; 2001 Sep; 116(3):420-8. PubMed ID: 11554171 [TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases. Lin P; Mansoor A; Bueso-Ramos C; Hao S; Lai R; Medeiros LJ Am J Clin Pathol; 2003 Aug; 120(2):246-53. PubMed ID: 12931555 [TBL] [Abstract][Full Text] [Related]
15. Pathology of macroglobulinemia--a review of Japanese cases. Yamaguchi K Acta Pathol Jpn; 1973 Nov; 23(4):917-52. PubMed ID: 4206123 [No Abstract] [Full Text] [Related]
16. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422 [TBL] [Abstract][Full Text] [Related]
17. Waldenstrom macroglobulinemia with CD5+ expression presented as cryoglobulinemic glomerulonephropathy: a case report. Kim YL; Gong SJ; Hwang YH; Joo JE; Cho YU; Lee JA; Sung SA; Lee SY; Kim NY J Korean Med Sci; 2011 Jun; 26(6):824-8. PubMed ID: 21655071 [TBL] [Abstract][Full Text] [Related]
18. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Ghobrial IM; Fonseca R; Greipp PR; Blood E; Rue M; Vesole DH; Gertz MA; Cancer; 2004 Dec; 101(11):2593-8. PubMed ID: 15493038 [TBL] [Abstract][Full Text] [Related]
19. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Cao X; Ye Q; Orlowski RZ; Wang X; Loghavi S; Tu M; Thomas SK; Shan J; Li S; Qazilbash M; Yin CC; Weber D; Miranda RN; Xu-Monette ZY; Medeiros LJ; Young KH J Hematol Oncol; 2015 Jun; 8():74. PubMed ID: 26104577 [TBL] [Abstract][Full Text] [Related]
20. IgM monoclonal gammopathy/Waldenström's macroglobulinemia: a morphological and immunophenotypic study of the bone marrow. Feiner HD; Rizk CC; Finfer MD; Bannan M; Gottesman SR; Chuba JV; Amorosi E Mod Pathol; 1990 May; 3(3):348-56. PubMed ID: 2114024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]